HeartBeam Study Shows Comparable Accuracy Between Portable 3D ECG System and Standard 12-Lead ECG

HeartBeam Inc. (NASDAQ: BEAT) announced study results showing no significant differences in detecting atrial fibrillation, atrial flutter and sinus rhythm when its deep learning algorithms were applied to the HeartBeam System versus standard 12-lead ECGs. Data from 201 patients, presented at HRX Live 2025 in Atlanta by Dr. Joshua Lampert of Mount Sinai Heart, demonstrated high accuracy rates in both groups with 94.5% for HeartBeam compared to 95.5% for standard 12-lead ECG.

The findings highlight the potential of HeartBeam's compact, 3D device to expand advanced cardiac monitoring to settings where full 12-lead ECGs may be impractical. CEO Rob Eno emphasized that this technology could revolutionize cardiac care by enabling accurate ECG monitoring outside traditional medical facilities. The company plans to use these results to support future FDA submissions for its innovative cardiac monitoring platform.

HeartBeam's technology represents a significant advancement in portable cardiac monitoring, creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located to deliver actionable heart intelligence. The 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while the 12-Lead ECG synthesis software remains under FDA review.

The implications of this study are substantial for the future of cardiac healthcare. By providing comparable accuracy to standard hospital equipment in a portable format, HeartBeam's system could enable earlier detection of cardiac conditions, reduce hospital visits, and allow for continuous monitoring in home settings. This technology has the potential to improve patient outcomes through more accessible and frequent cardiac monitoring while reducing healthcare costs associated with traditional ECG procedures.

For investors and the medical community, these results validate HeartBeam's approach to transforming cardiac care with personalized insights. The company's extensive intellectual property portfolio, including over 20 issued patents related to technology enablement, positions it as a leader in the evolving field of remote cardiac monitoring solutions. The full study details are available through the company's official communication channels at https://ibn.fm/BDiIa.